An open-label, randomized, controlled trial to assess the efficacy and safety of teprenone in chronic hepatitis C patients concurrent with chronic gastritis treated with peginterferon alpha-2b plus ribavirin.

Trial Profile

An open-label, randomized, controlled trial to assess the efficacy and safety of teprenone in chronic hepatitis C patients concurrent with chronic gastritis treated with peginterferon alpha-2b plus ribavirin.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2013

At a glance

  • Drugs Teprenone (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Gastritis; Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
    • 26 Apr 2011 Planned end date changed from 1 Mar 2012 to 1 Dec 2013 as reported by University Hospital Medical Information Network - Japan
    • 02 Mar 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top